chartexchange

MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib

Clinical Trials Arena | Nov 18, 2026 4:44 AM EST

MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib for leukaemia and other haematologic malignancies after eDMC review.
The post MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib appeared first on Clinical Trials Arena .

Read original article